-
Article
Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM)
Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on ...
-
Article
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma
Bevacizumab blocks the effects of VEGF and may allow for more aggressive radiotherapy schedules. We evaluated the efficacy and toxicity of hypofractionated intensity-modulated radiation therapy with concurrent...
-
Article
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide
To report health-related quality of life (HRQOL) in glioblastoma (GBM) patients treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with temozolomide (TMZ). GBM patient...
-
Article
Genetic characterization of gliomas arising in patients with multiple sclerosis
The co-occurrence of gliomas and multiple sclerosis (MS) in the same patient is uncommon, but a well-reported phenomenon. Most have been high grade astrocytic tumors that developed after the diagnosis of MS, l...
-
Article
The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis
Bevacizumab (Avastin, Genetech/Roche) is an anti-angiogenic drug approved for treating patients with malignant gliomas that reduces edema and mass effect, but has been suggested to promote multifocal tumor spr...
